Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2600731rdf:typepubmed:Citationlld:pubmed
pubmed-article:2600731lifeskim:mentionsumls-concept:C0010558lld:lifeskim
pubmed-article:2600731lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:2600731lifeskim:mentionsumls-concept:C0524527lld:lifeskim
pubmed-article:2600731lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:2600731lifeskim:mentionsumls-concept:C0051482lld:lifeskim
pubmed-article:2600731pubmed:issue6lld:pubmed
pubmed-article:2600731pubmed:dateCreated1990-2-2lld:pubmed
pubmed-article:2600731pubmed:abstractTextThe poor water solubility of alfaxalone (less than 5 micrograms/mL), a useful steroid anesthetic agent, was dramatically increased via complexation with a series of four cyclodextrins. The most effective agent was 2-hydroxypropyl-beta-cyclodextrin (2HPCD) which solubilized alfaxalone in a linear manner as a function of concentration. At a 2HPCD concentration of 50% w/v, approximately 80 mg/mL of alfaxalone was dissolved indicating an increase in aqueous solubility of over four orders of magnitude. The cyclodextrin solution was stable to autoclaving and could be conveniently lyophilized to yield a solid product.lld:pubmed
pubmed-article:2600731pubmed:languageenglld:pubmed
pubmed-article:2600731pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:citationSubsetIMlld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2600731pubmed:statusMEDLINElld:pubmed
pubmed-article:2600731pubmed:issn0279-7976lld:pubmed
pubmed-article:2600731pubmed:authorpubmed-author:BodorNNlld:pubmed
pubmed-article:2600731pubmed:authorpubmed-author:EstesK SKSlld:pubmed
pubmed-article:2600731pubmed:authorpubmed-author:BrewsterM EMElld:pubmed
pubmed-article:2600731pubmed:issnTypePrintlld:pubmed
pubmed-article:2600731pubmed:volume43lld:pubmed
pubmed-article:2600731pubmed:ownerNLMlld:pubmed
pubmed-article:2600731pubmed:authorsCompleteYlld:pubmed
pubmed-article:2600731pubmed:pagination262-5lld:pubmed
pubmed-article:2600731pubmed:dateRevised2000-12-18lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:meshHeadingpubmed-meshheading:2600731-...lld:pubmed
pubmed-article:2600731pubmed:articleTitleDevelopment of a non-surfactant formulation for alfaxalone through the use of chemically-modified cyclodextrins.lld:pubmed
pubmed-article:2600731pubmed:publicationTypeJournal Articlelld:pubmed